Arrowhead Pharmaceuticals reported early clinical results suggesting its brain-targeting RNA interference medicine can reduce tau protein levels in humans. In a trial in healthy volunteers, the company said the highest dose given as two subcutaneous injections spaced two weeks apart reduced tau by an average of 73% after 105 days. The readout is being positioned as evidence that systemic administration can achieve central nervous system delivery and functional target engagement—an ongoing challenge for RNAi programs constrained by the blood-brain barrier. The company’s focus is currently on safety and confirmation that exposure translates into pharmacodynamic effects. For Alzheimer’s drug development, tau remains a key target amid modest clinical benefits for existing anti-amyloid approaches. Next milestones will include clearer dose-response characterization, durability of tau lowering, and progression into patient studies designed to test clinical relevance.